Continue to Site

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Medtronic reveals steep COVID-19 financial impact

Medtronic reveals steep COVID-19 financial impact

By

Medtronic logo updatedMedtronic (NYSE:MDT) issued a financial update revealing that weekly revenue in the U.S. is down 60% amid the COVID-19 pandemic.

The Fridley, Minn.-based medtech giant explained in a news release that the business impact remains fluid, but the company expects COVID-19 to negatively affect its fourth-quarter (ended April 24) results, and the quarter will reflect an additional month of impact compared to other companies on a calendar-based fiscal year.

Certain product lines are in high demand as a result of COVID-19, including products from Medtronic’s cardiac & vascular group, minimally invasive therapies group and diabetes group, which make up approximately 10% of the company’s pre-coronavirus global revenue.
Weekly revenue is down approximately 60% on its year-over-year average in the U.S., which represented approximately 53% of Medtronic’s total revenue before COVID-19. Revenue in China is down 50% year-over-year and it is down approximately 20-30% year-over-year in Western Europe.
Medtronic said it has continued to invest in R&D and its employees, including its sales force, and it continues to make progress with its pipeline and work with regulatory authorities on timelines that the pandemic hasn’t affected. The company has placed clinical trials that are currently enrolling on temporary pause to allow for hospitals to focus on COVID-19.
The company cited a strong balance sheet with approximately $11 billion in cash and investments as of the most recent quarter, along with an undrawn $3.5 billion credit facility and no public debt maturing until March 2021. It plans to continue making capital allocation decisions to progress its long-term strategies.
“While the expected short-term impact to our financial results is significant, it is consistent with the impact discussion broadly across the medical device industry,” Medtronic president Geoff Martha said in the news release. “Importantly, we are starting to enter the early stages of a global recovery. As hospitals begin to resume broader treatment of non-COVID-19 patients around the world, we expect our business to begin to recover as well.
“In addition, given the financial strength of the company, we are executing strategies to come out of this pandemic even stronger, attracting and retaining top talent and increasing and innovating the products and services that we offer physicians, patients, and healthcare systems to win in the evolving marketplace.”

Medtronic also explained that its manufacturing and distribution facilities are sanitized, its employees are utilizing personal protective equipment (PPE) and practicing social distancing and the company implemented additional screening and access protocols.

Field employees are provided access to PPE, and Medtronic is offering its U.S. employees and their family members a free virtual COVID-19 evaluation and monitoring tool. The company also included coronavirus-related benefits, such as reward programs, protection from impacts to sales incentive compensation, emergency leave pay for employees whose roles can’t be performed remotely and increased contributions to its employee emergency assistance fund for those experiencing a financial impact due to COVID-19.

“I am incredibly proud of the response of our 90,000 global employees,” Medtronic chairman & CEO Omar Ishrak said. “I want to recognize and thank our customers, partners, and the healthcare community at large, for their efforts to combat this pandemic. Individually, and collectively, we will persevere.”

In case you missed it

RSS From Medical Design & Outsourcing

  • Synchron’s plan to beat Neuralink in the neuroprosthetic BCI race
    Competing brain-computer interface (BCI) developers Synchron and Neuralink both announced big news this month as they move their dueling neuroimplant technologies forward. The device developers each have FDA investigational device exemption (IDE) for their experimental BCIs. They’ve also got billionaires backing their R&D and regulatory efforts, with Neuralink owned by Elon Musk and Synchron funded… […]
  • How LimFlow’s foot-saving system prevents amputations in patients with no other options
    LimFlow’s breakthrough system for treating chronic limb-threatening ischemia (CLTI) is the first of its kind approved by the FDA for this severe form of peripheral artery disease (PAD). For CLTI patients who have lost blood flow below their knee and have no other suitable endovascular or surgical treatment options available, the LimFlow System for Transcatheter… […]
  • Device strategies to prevent healthcare-associated infections
    Device design, sterilization before use and proper cleaning of reusable equipment can prevent infections and save lives. By Ted Eveleth, AvantGuard Nosocomial infections, also commonly known as healthcare-associated infections (HAIs), are a multibillion-dollar problem and a leading cause of morbidity and mortality around the world. On any given day, about 1 in 31 hospital patients… […]
  • MGS breaks ground on innovation and tech center
    MGS has started construction of its new innovation center at its headquarters campus in Germantown, Wisconsin. The medtech contract manufacturer said the 120,000 ft² facility is scheduled to open by the end of 2024. The MGS expansion will have collaborative workspaces dedicated to ideation and product development, tooling development, automation, and part and process validation,… […]
  • Two-armed surgical robot prototype targets pediatric brain tumors
    Researchers say they’ve developed a surgical robot for removing brain tumors in children, and that it could also offer a less invasive, safer option for adult neurosurgery and other procedures. The trick is using hollow, nitinol robot arms to allow neurosurgeons to swap tools during a tumor resection procedure, said Pierre DuPont. He’s the chief… […]
  • S3 Connected Health joins DiMe’s International Regulatory Pathways project
    NEWS RELEASE: S3 Connected Health joins DiMe’s team of digital health experts in their new project ‘International Regulatory Pathways’ DUBLIN, September 19, 2023 – Building on the success of the Digital Health US Regulatory Pathways, DiMe has assembled a global team of digital health experts, including S3 Connected Health, to support digital health product developers… […]
  • Four steps medtech startups can’t put off
    Developing and commercializing a new medical device is a success worth toasting for medtech startups — but that success also makes it more likely that litigation is in their future. There are steps medtech startups can take to protect themselves down the road, said Greenberg Traurig shareholder Ginger Pigott, a litigator who defends major medical… […]
  • How Biosense Webster aims to expand access to AFib care
    Electrophysiology is “an incredibly vibrant space,” said Nikki Sidi, but access remains a challenge. Nikki Sidi, the U.S. president of Johnson & Johnson’s Biosense Webster, can look at her own company as one of those paving the way in electrophysiology (EP). Its recent milestones include multiple atrial fibrillation (AFib) mapping catheters, including ablation and mapping devices. … […]
  • Tessy Plastics announces CEO and president transitions
    Tessy Plastics today named Stafford Frearson as the medtech supplier’s new president with former President Roland Beck becoming CEO. Frearson joined the contract manufacturer in 1997 and was promoted to his most recent role, VP of engineering, in 2018. He’s now responsible for day-to-day business operations across the plastics company’s 13 locations in the U.S.… […]
  • Accumold details injection molding of thin wall cannulas
    NEWS RELEASE: Injection molding of thin wall cannulas — a lesson in expertise and persistence After 5 years of painstaking work, leading micro molding innovator Accumold has developed a way to micro injection mold thin wall cannulas in very high volumes. Previous to this innovative approach to production, cannulas were typically produced via an extrusion… […]
  • How exposed are Medtronic, Intuitive and other Medtech Big 100 device makers to China?
    As economic concerns shift from the U.S. to China, medical device manufacturers such as Medtronic and Intuitive are monitoring how procedure volumes and new policies affect their businesses. In a new note, William Blair analyst Brandon Vazquez details the exposure of those companies and four more on Medical Design & Outsourcing‘s Medtech Big 100 ranking… […]

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Copyright © 2023 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy